Expansion of umbilical cord derived mesenchymal stem cells with human serum and human platelet lysate

      As currently available literature shows, mesenchymal stem cells (MSC) represent an immense potential in clinical applications. Their immunomodulatory properties and their differentiation capacity at least into osteoblasts, chondroblasts and adipocytes, make many diseases a scope of application. Collection from bone marrow, the most commonly used source of MSC, represents an extremely invasive and painful collection procedure. Therefore, human umbilical cords (hUC) would be a perfect substitute. For cultivation fetal calf serum (FCS) is preferred until now, despite ethical concerns and the risk of disease transmission. Since also human serum (huS) and human platelet lysate (hPL) could be used as media supplements for MSC, a comparison was performed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect